Background/Objectives: Parkinson’s disease (PD) and hypertension are often coexistent conditions that interact in entwined ways at various levels. Cardiovascular autonomic dysfunction (CAD), a non-motor feature of PD occurring across all stages, alters blood pressure (BP) regulation. Methods: We conducted a cross-sectional study enrolling patients with PD and primary hypertension, without diabetes mellitus or other causes of secondary CAD, aiming to characterize BP profiles/patterns by ambulatory BP monitoring. We also sought associations between different CAD phenotypes and PD characteristics, disability, and cardiovascular comorbidities. Results: We included 47 patients with a median age of 71 years, PD duration of 9 years, and Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III score of 40. Diurnal and nocturnal BP values were within the reference range, but BP load was excessive. Almost one-third had neurogenic orthostatic hypotension (OH) and 80% were non-dippers. The overall burden of non-motor symptoms was significant in these phenotypes. Patients with neurogenic OH were more prone to constipation, anxiety, and urinary problems, whereas gustatory dysfunction, loss of libido, and erectile dysfunction were more frequently reported by non-dippers. No significant differences with regard to cognitive decline were identified in subjects with and without neurogenic OH. Neurogenic OH was symptomatic in 78% of the cases, whereas 56% of those with orthostatic symptoms did not have OH at repeated measurements. Conclusions: Neurogenic OH is an independent predictor of disability in patients with PD and hypertension, after adjusting for PD duration, Hoehn and Yahr stage, levodopa equivalent daily dose (LEDD), and Montreal Cognitive Assessment (MoCA) score.

Background/Objectives: The goal of this study was to assess the correlation between ultrasound measurements and nerve conduction study (NCS)-defined carpal tunnel syndrome (CTS) severity and to explore clinical and demographic factors associated with CTS severity in a sample of Romanian patients. Methods: We prospectively evaluated consecutive patients with clinically diagnosed CTS. All patients underwent standardized clinical assessment, ultrasonographic examination of the median nerve, and NCS. CTS severity was graded electrophysiologically (three-level scale), and associations with demographic, clinical, and ultrasound parameters were examined using univariate analyses and multivariable generalized estimating equation (GEE) models to account for within-patient clustering. Results: Among 193 CTS hands (100 patients, mean age 58 years, 93% female), electrophysiological severity correlated significantly with several ultrasound and clinical parameters. In multivariable GEE models, the presence of nocturnal symptoms, sensory loss, thenar weakness/atrophy, male sex, larger maximal median nerve cross-sectional area (mCSA), and impaired median nerve mobility were independent predictors of higher NCS-defined severity. Pseudo-R² increased from 0.04 in the core clinical model to 0.25 when ultrasound parameters were included, indicating improved model performance. Conclusions: Ultrasound parameters, particularly mCSA and median nerve mobility, together with clinical features, such as nocturnal symptoms, sensory loss, and thenar weakness, are independently associated with NCS-defined CTS severity. These findings support the complementary role of ultrasound alongside NCS in severity grading and highlight its potential to guide timely diagnosis and management.

Background/Objectives: Peripheral neuropathy (PN) is an increasingly recognized complication of device-assisted therapies for advanced Parkinson’s disease, with reported frequencies ranging from 1% to nearly 50% and no pooled estimate available. We aimed to estimate how often PN is reported under device-assisted therapy and whether its frequency is associated with levodopa exposure, catechol-O-methyltransferase (COMT) inhibition, and vitamin status. Methods: PubMed, Scopus, and Web of Science were searched without date restriction, and the reference lists of 21 reviews were screened. Studies reporting a peripheral nerve outcome under any device-assisted therapy were eligible, and proportions were pooled using random-effects models (PROSPERO CRD 1375888). Results: Seventy-five studies with 7106 patients were included. The pooled frequency under levodopa–carbidopa intestinal gel (LCIG) was 13.2% (95% confidence interval 9.8 to 17.6), against one case among 272 patients under levodopa-entacapone-carbidopa intestinal gel (LECIG). Frequency rose with levodopa dose (odds ratio 1.28 per 100 mg/day) and treatment duration (1.30 per 12 months). Neither COMT inhibition nor prophylactic B-vitamin supplementation was associated with lower frequency. Reported frequency ranged from 3.9%, where PN was recorded only when volunteered, to 33.6%, where all patients were tested. Conclusions: How intensively PN is sought appears to be a major determinant of how often it is found.

Background/Objectives: The independent contribution of extent of resection (EOR) to early recurrence in diffuse gliomas remains debated, as crude analyses are confounded by tumor biology, and real-world data from Eastern European centers are scarce. Methods: We retrospectively studied 283 consecutive adults with surgically treated diffuse gliomas (2021–2024) at a Romanian tertiary center. Primary endpoints were recurrence-free survival (RFS) at 1 and 2 years, evaluated as landmark endpoints; secondary endpoints were overall recurrence, reoperation, and reirradiation. Clinical, histopathological, surgical, imaging, and treatment variables were analyzed with complete-case Firth-penalized logistic regression. Results: Among evaluable patients, 70.6% (132/187) were recurrence-free at 1 year and 64.2% (120/187) at 2 years; overall recurrence occurred in 53.7% (139/259). After adjustment, gross total resection (GTR) was independently associated with higher odds of remaining recurrence-free at 1 year (OR 12.37, 95% CI 3.23–52.58; p < 0.001) and 2 years (OR 10.56; p < 0.001), as was subtotal resection (STR) at both time points (OR 4.15, 95% CI 1.17–16.16, p = 0.027; and OR 3.93, p = 0.027), versus partial resection/biopsy. Conclusions: EOR was independently associated with early RFS, supporting maximal safe resection as a primary surgical objective. The landmark endpoints were not evaluable in 96 of 283 patients, almost all of whom underwent biopsy or partial resection, so the odds ratios indicate the direction of the effect and not its precise magnitude. Overall recurrence, evaluable in 91.5% of the cohort, showed a concordant gradient. External validation is needed.